The FDA granted breakthrough therapy designation to efimosfermin — an investigational, once-monthly fibroblast growth factor ...

Fibroblast growth factor 21 (FGF21) analogs significantly improve fibrosis and resolve metabolic dysfunction-associated steatohepatitis (MASH) without progression, showing promise for non-cirrhotic ...

Heart failure (HF) is one of the leading causes of death and disability worldwide, affecting millions of people and placing an enormous burden on healthcare systems. The disease occurs when the heart ...

Fibroblast activation protein (FAP) is a serine protease, the expression of which increases with pathogenic fibroblasts in the fibrotic liver during metabolic dysfunction-associated steatohepatitis ...

A new case-control study published in JAMA Cardiology demonstrates that molecular imaging using gallium-68–labeled fibroblast ...

Heart failure occurs when the heart can no longer pump blood efficiently to meet the body’s needs. Beyond weakened muscle cells, new research highlights the hidden role of fibroblasts—supporting cells ...